Current CML therapy: Progress and dilemma

Leukemia

Volumn 17, Issue 6, 2003, Pages 1010-1012

  Hehlmann, R ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CML; Imatinib; Interferon ; Prognostic scores; Stem cell transplantation; Treatment algorithm

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; HYDROXYUREA; IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER REGRESSION; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DISEASE COURSE; DRUG POTENCY; HIGH RISK PATIENT; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0037668888     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2402951     Document Type: Review

References (20)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
2. O'Brien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F et al. The IRIS study: International randomized study of interferon and low-dose ara-C versus STI571 (imatinib) in patients with newly-diagnosed chronic phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.
3. Hasford J, Pfirrmann M, Hehlmann R, Allan NC, Baccarani M, Kluin-Nelemans J et al. A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa. J Natl Cancer Inst 1998; 90: 850-858.
4. Silver RT, Woolf SH, Hehlmann R, Appelbaum FA, Anderson J, Bennett C et al. Review: an evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999; 94: 1517-1536.
5. Hansen JA, Gooley TA, Martin PJ, Appelbaum F, Chauncey TR, Clift RA et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
6. Gratwohl A, Hermans J, Goldman JM, Frassoni F, Devergie A, Carreras E et al. for the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087-1092.
7. van Rhee F, Szydlo RM, Hermans J, Devergie A, Frassoni F, Arcese W et al. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation European results of matched unrelated donor bone marrow transplantation for chronic myeloid leukemia. Impact of HLA class II matching. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 11-19.
8. Cross NCP, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993; 82: 1929-1936.
9. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Müller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
10. Hehlmann R. Trial of IFN or STI571 before proceeding to allografting for CML? Leukemia 2000; 14: 1560-1562.
11. Hochhaus A, Reiter A, Saussele S, Reichert A, Emig M, Kaeda J et al. Molecular heterogeneity in complete cytogenetic responders after interferon alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. Blood 2000; 95: 62-66.
12. Bonifazi F, De Vivo A, Rosti G, Guilhot F, Guilhot J, Trabacchi E et al. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001; 98: 3074-3081.
13. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645-652.
14. Burchert A, Wolfl S, Schmidt M, Brendel C, Denecke B, Cai D et al. interferon-alpha, but not the ABL-kinase inhibitor imatinib (STI571), induces expression of myeloblastin and a specific T-cell response in chronic myeloid leukemia. Blood 2003; 101: 259-264.
15. Hehlmann R, Berger U, Pfirrmann M, Hochhaus A, Metzgerdth G, Maywald O et al. Randomized comparison of interferon α and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-Study II): prolongation of survival by the combination of interferon α and hydoxyurea. Leukemia 2003 (in press).
16. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99: 1928-1937.
17. Lipton JH, Khoroshko ND, Golenkov AK, Abdulkadyrov KM, Nair MK, Raghunadharao D et al. A randomized multicenter comparative study of peginterferon alfa-2a (40KD) vs interferon-alfa-2a in patients with treatment-naive chronic-phase chronic myelogenous leukemia. Blood. 2002; 100: 782a.
18. Hoover RR, Mahon FX, Melo JV, Daley GQ. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood 2002; 100: 1068-1071.
19. La Rosee P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 2002; 16: 1213-1219.
20. Hehlmann R, Berger U, Engelich G. Imatinib-Kombinationstherapien - die neue CML - Studie IV. Dtsch Med Wochenschr 2002; 127: 2224-2226.